Alebund Pharmaceuticals
Manufacturing · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1206 Hong Kong Plaza South Tower 283 Cen...Phone Number
+86 2160836212Website
www.alebund.comRevenue
$15.5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Alebund Pharmaceuticals
Alebund is a clinical stage biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions.Explore more
Popular SearchesAlebund PharmaceuticalsAlebund Pharmaceuticals LtdSIC Code 28,283NAICS Code 32,325Show moreAlebund Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alebund Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Alebund Pharmaceuticals launches new products
Click to see if Alebund Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Alebund Pharmaceuticals has new funding data
Alebund Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Alebund Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Alebund Pharmaceuticals
Check if Alebund Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Alebund Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Alebund Pharmaceuticals as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Alebund Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alebund Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alebund Pharmaceuticals.
Alebund Pharmaceuticals financials insights
Gather financial insights about Alebund Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series B
$60M
Other Financing Round
$54.5M
2025
Series C
$70.1M
Alebund Pharmaceuticals Tech Stack
A closer look at the technologies used by Alebund Pharmaceuticals
See more technologies
Most Recent Scoops
Funding
Funding
Funding
Funding
Funding
Alebund Pharmaceuticals News & Media
Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase IIb Multi-Regional Clinical Trial of AP306 for Hyperphosphatemia
SHANGHAI, July 21, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the first participant has been randomized and dosed in the global Phase IIb multi-regional clinical...Alebund Pharmaceuticals (09637.HK) Debuts on the HKEx Main Board
Deepening Its Commitment to Kidney Disease and Accelerating Toward Becoming a Global Leader in Renal Innovation SHANGHAI, June 29, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a biopharmaceutical company focused on...Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia
SHANGHAI, May 6, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, today announced the...Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis Alebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Alebund Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Alebund is a clinical stage biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions.... Read More
